A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma

LESSONS LEARNED. Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments. The observation of three responses among the 30 patients with median progression‐free survival and overall survival of 8.3 and 15 months, respectively, indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burotto, Mauricio, Edgerly, Maureen, Velarde, Margarita, Balasubramaniam, Sanjeeve, Drabkin, Harry, Gormaz, Juan G., O'Sullivan, Ciara, Madan, Ravi, Fojo, Tito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553966/
https://www.ncbi.nlm.nih.gov/pubmed/28679644
http://dx.doi.org/10.1634/theoncologist.2017-0211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553966/
https://www.ncbi.nlm.nih.gov/pubmed/28679644
http://dx.doi.org/10.1634/theoncologist.2017-0211

Ejemplares similares